NULOJIX 250 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION

EUEMA:by INNUSDailyMed:BelataceptUSFDA:Belatacept AU:C L04AA28(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-only 706808-37-9Y DB06681Y None E3B2GI648A D03222 Belatacept, sold under the brand nameNulojix, is afusion proteincomposed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain ofCTLA-4,which is a molecule crucial in the regulation of T cellcostimulation, selectively blocking the process of T-cell activation. It is intended to provide extendedgraftandtransplantsurvival while limiting the toxicity generated bystandard immune suppressing regimens, such ascalcineurin inhibitors. It differs fromabatacept(Orencia) by only two amino acids.[medical citation needed] Belatacept was developed byBristol-Myers-Squibband approved by the U.S.Food and Drug Administration(FDA) on June 15, 2011.